British American Tobacco p.l.c. (BATS) Earnings Call Transcript & Summary
July 31, 2020
Earnings Call Speaker Segments
Jack Bowles
executiveGood morning, everyone, and welcome to BAT's presentation of our 2020 interim results. I'm Jack Bowles, Chief Executive, and Tadeu Marroco, our Finance Director, is here with me today. I hope all of you listening this morning, along with your families and friends, are well. Before I begin the presentation, I need to point you to the disclaimer on slide number two and slide number three, which I'll treat as read. I'm very proud to report that in the first half of 2020, our multi-category strategy has kept on delivering growth in what has been an exceptionally challenging circumstance. These results show that our strategy is delivering growth in all key metrics — revenue, operating profit, EPS, and cash — driven by growing volume share in THP, value share in vapor, and revenue in Modern Oral, alongside combustible and strong pricing. Our increased agility, brought about through Quantum and our diverse geographic footprint, let us adapt and navigate the challenges caused by COVID. We remain committed to delivering a strong operational performance and our dividend policy. We are building a better tomorrow. With our defining corporate purpose and an ESG strategy that sits front and center of everything we do, we have made strong progress in 2020.
Jack Bowles
executiveAt this point, non-combustible accounts for 10% of revenues for the group. We've kept putting more money into the business, drawing an extra 2.7 million consumers to our non-combustible products versus a year ago. After bringing in 1.1 million new consumers in the first half, right through the worst of the pandemic, we've also established demanding environmental goals. It's clear we're moving ahead with force. Because we're concentrating on our three clear commercial priorities, we're delivering now while investing for what's ahead. We keep pushing a step change in how the new category performs, with share gains in the market and 12.7% adjusted revenue growth at constant currency. Our ongoing emphasis on value growth in combustibles produced solid cigarette price mix along with adjusted revenue of 2.4% at constant currency. What Project Quantum has delivered — a stronger, simpler, and faster organization — has let us steer through COVID with more agility at the same time as generating GBP 240 million in cost savings year to date. We're committed to delivering, and I want to use this moment to thank our people, who have gone above and beyond in producing these results under very challenging circumstances. Now to the numbers. Reported results gain from the effect of the Quebec class action on the prior-year comparison and mirror a foreign exchange headwind of roughly 1%.
Jack Bowles
executiveTo get a clearer picture of what's really driving our results, we'll turn now to constant currency adjusted figures, unless we say otherwise. Across all four regions, in combustibles, we're gaining share nearly everywhere. Every key metric moved higher for us. Revenue, profit and EPS all increased, even with a 4% revenue headwind from COVID in the first half. Cigarettes and THP volume fell -6.3%, or 5.3% if you strip out global travel retail. That compares with an industry decline of roughly 6%, excluding GTR. Our expectation for the full year remains that global industry volume will decline around 7%, excluding GTR. Solid cigarette price mix plus new category results lifted total group revenue 2.4%. Adjusted operating profit rose 3.3%, outpacing revenue growth, which shows tight cost control and the early gains from Project Quantum. That's a strong result in difficult conditions. The 4% revenue headwind from COVID in the first half came from reduced international travel hitting GTR, along with differing experiences in developed and emerging markets. In developed markets, roughly 75% of our revenues, consumption trends have mostly held up or even edged slightly better, with good pricing. So far, we've found little sign of an accelerating downtrend.
Jack Bowles
executiveLooking at emerging markets, which make up roughly 25% of revenue, the situation has been somewhat more uneven. Governments in certain markets have required factories to close and imposed tighter lockdowns, and those steps have heavily affected shoppers' capacity to get hold of our products. In South Africa alone, cigarette sales have been prohibited since late March, and that prohibition is still in force. On the other hand, in markets like Brazil, we have found that shutting borders has helped industry volumes by cutting back illicit trade. Even with the strain caused by COVID, our volume share has risen in developed and emerging markets alike. New category growth dipped at first but is now coming back. Within new categories, we moved fast to adapt to the changed conditions, drawing on our digital strengths, putting money into consumer acquisition, and lifting our volume share in THP, our value share in vapor, and revenue in Modern Oral. Across our three strategic brand platforms, progress is solid. Consumer numbers are up 2.7 million, and revenue has climbed by almost 13%, even in this difficult environment. During the first half, we put an extra GBP 250 million into new categories. Thanks to our sharp emphasis on consumer acquisition and digital, we now hold the lead in device sales in vapor.
Jack Bowles
executiveOur e-commerce sales have doubled, and the time from prototype to launch has been cut in half. That gives us a solid foundation going forward. When the pandemic hit, we moved our consumer activations into digital successfully, and we achieved best-in-class consumer engagement readings across all three category brand platforms. Now turning to each category. In vapor, with consumer numbers now above 6 million, we turned in an excellent performance. The key vapor markets are growing strongly in the first half. Vuse's Vype is gaining value share in every key market. We added over 2 million consumers compared with the same period last year, and we delivered 39% revenue growth in vapor. That was driven by an excellent performance from our strategic brands, Vuse with Vype, which tripled its total value share across our T5 markets versus the same period last year. The T5 markets account for 80% of total vapor industry revenue. In the U.S., Vuse's Alto tripled its value share year-on-year, pushing revenue up 17%. This performance came against the backdrop of industry dynamics over the last 12 months, which have not been easy. In the second half of last year, concerns in the U.S., specifically around youth vaping trends and the EVALI crisis, led to a broad-based decline in the vapor industry across our top five markets.
Jack Bowles
executiveWe’re seeing a strong recovery, and most markets are now above where they were before the crisis. Over the past three months, industry growth rates have been very encouraging. In every key market, Vuse Vype has posted strong value share gains. The brand now leads in device sales across all key markets. Clearly, putting devices in consumers’ hands is essential for conversion. We view that as a leading indicator of the category growth we expect ahead. Last year, to strengthen our portfolio further, we chose to move to three global new category brands. Vapour brand migrations have kept going during this period, and 70% of Vapour revenue is now under the Vuse brand. Canada is a great example. In Canada, share gains sped up as Vype was migrated to Vuse. The migration plan was run through digital channels, created record levels of consumer awareness, and benefited from our many years of successful experience with combustible brand migration. Online sales rose 50% sequentially in Q2. Our share of device sales hit 70%. Retention rates came in at 100% throughout the migration. Vuse surpassed 44% share in June. We’re especially pleased with these results because the work was finished while lockdown restrictions were in place in Canada.
Jack Bowles
executiveMoving on to how we did in THP. Consistent with our ambitious innovation roadmap for THP, which follows last year's launch of glo Pro, we've begun rolling out Hyper, which reinforces the glo portfolio. Across our key markets, we've reached our highest volume share position for glo. The early success of glo Hyper in the launch markets, together with the better consumer satisfaction it delivers, has driven this. Hyper's launch and activation plans were moved to digital, and the early results leave us extremely encouraged. During Q2, Hyper is fueling share growth in Japan and India alike. In Moscow, glo segment share has doubled to 16%, and total nicotine share has climbed to 2.8%. Rollouts have begun in Italy and other markets in ENA. That has produced good growth in consumable volumes, which rose 9.1%. THP revenue for the period fell 12%, reflecting the excise harmonization in Japan and the underperformance of glo sens, our hybrid platform. glo Hyper's better product performance stems from several advancements that have materially raised consumer satisfaction. Among them is powerful new induction. It delivers a fast ramp-up time along with a boost function, providing extra satisfaction and impact.
Jack Bowles
executiveA new consumable that contains 30% more tobacco, in a familiar premium king stick format, gives you more taste and flavor. It has earned strong consumer acceptance scores, with research indicating 80% overall likeability when it comes to taste satisfaction, flavor, and taste intensity. In Japan, helped by the success of glo Hyper, total glo volume share now stands at 5.4% in June and hit a June exit volume share of 5.9%, the highest level ever recorded. 37% of Hyper consumers are new to the franchise, and conversion rates from trial to regular usage sit at 50%, twice the previous level. Both are solid indicators of the future growth outlook. After 12 weeks, Hyper has posted a June monthly volume share of 0.7% and achieved a weekly exit volume share of 1.3% at the end of June. In modern oral, we are growing revenue in a category that is expanding quickly, with an exciting opportunity ahead. We have reinforced our leadership position in Scandinavia and remain leaders outside the U.S. Also, in emerging markets, we are setting up a supply chain and manufacturing for final launches in APMEA and AMSA. With encouraging initial results, these pilots provide. In the U.S., it is a nascent yet promising category with around 1% total nicotine value share, compared to traditional oral at more than 10% total nicotine value share.
Jack Bowles
executiveSo far this year, we've increased our share in the U.S. with a limited product range. That's supporting short-term growth in what is a highly competitive category. We're working hard to close the portfolio gaps. Doing so will mean navigating the FDA regulatory framework, and that will take some time. Globally, Modern Oral is an exciting category with high growth, high margins, a rapid payback, and significant potential. We have a winning portfolio in Scandinavia and continue to build on our strong market share position. While consumer activation for more recent launches have been impacted by COVID, we have a program of rollouts planned for the second half, building on encouraging pilots in APMEA and AMSA. It is clearly still early days for this exciting category. In the key Nordic markets, we are consolidating our leadership position with our superior products, reaching 14.7% of the Norwegian and 4.5% of the Swedish total oral market in June. In summary, in new categories, we are driving growth through consumer acquisition. We continue to invest with an additional GBP 250 million in new categories marketing in the first half. We have attracted an additional 2.7 million new consumers to our non-combustible products year-on-year and continue to add to our consumer base throughout the pandemic.
Jack Bowles
executiveWe've adjusted to the obstacles presented by COVID, moving over to digital activation, and produced results including share gains in vapor and THP across every region plus robust revenue growth in Modern Oral. Turning to combustible. We turned in an outstanding performance. Volume and value share are rising worldwide, with gains in each region. In the U.S., we keep pushing revenue growth forward, posting strong results. Global volume share rose 50 basis points — among the best performances we've ever had — while value share climbed 20 basis points. That came from a 40 basis points value share gain in strategic brands, which make up two-thirds of group volume. Those share gains, together with a strong price mix of 8.5%, combined to lift combustible revenue by 2.2%, even as industry volume declined. Our brand portfolio is well balanced across a wide geographic footprint. This has produced steady growth throughout all price segments in the cluster. Down trading has been a feature in certain markets over recent years, and it carried on. Even so, we haven't observed any acceleration in down trading during the period, and our portfolio sits in a good position across all price points. Our strongly differentiated brand portfolio keeps generating share growth across all the key consumer segments — in freshness and stimulation, slim performer, and in non-filter flavors.
Jack Bowles
executiveWe're also seeing results from prioritizing value growth in developed markets and volume growth in emerging ones — value share there rose 30 basis points, while emerging markets saw volume share climb 70 basis points. Here in the U.S., we've grown revenue by moving pricing ahead of peers, and we kept expanding combustible value and volume share thanks to the strength of our brand portfolio. That drove adjusted revenue and profit each up 10%. Value share rose 30 basis points, and volume share increased 10 basis points. Reynolds posted a corporate volume share of 35%, with Newport at 15%, and Natural American Spirit kept performing strongly, lifting premium volume share by 50 basis points. U.S. industry cigarette volume rose 0.8% in the period, helped by stronger consumption trends, a smaller drag on cigarette consumption from vaping, higher inventories throughout the supply chain, and one additional selling day. For the full year, we now project U.S. industry volume will decline roughly 2.5%, reflecting continued resilience in consumer demand and elevated trade stock levels that are being kept up because of COVID. New category revenue climbed 76%, led by U.S.
Jack Bowles
executiveGains in vapour value share came to 10 percentage points. In the U.S., the Vapour category is bouncing back, with 20% growth over the last three months. Our strategy across multiple categories is producing solid share gains in total nicotine within the U.S. Total nicotine value share rose 70 basis points, while volume share climbed 60 basis points. As we look toward H2, consumer fundamentals continue to look robust and lockdown restrictions are loosening. These results show we can successfully steer through the pandemic, though the environment is still uncertain. Our global travel retail business continues to be substantially affected, and we don't expect a recovery before late in the year. In South Africa, cigarettes and the reinstated alcohol sales ban are in place. We are challenging the ban, and the court hearing, after some delay, is now set for August. We believe our case is strong. Although COVID-related uncertainties persist, we are planning for the sequential recovery to carry on through the second half. South Africa remains a unique situation. We had a very strong first quarter, with volumes up 10%, driven by a reduction in illicit trade. Since the sales ban was imposed in March, the entire market has shifted into illicit. In addition, illicit prices have tripled compared with prices before lockdown and have created product availability issues around the country.
Jack Bowles
executiveSo because of this, the government has lost GBP 340 billion in excise and VAT, and is now facing a continuing profit impact of GBP 25 million each month. We’re looking ahead to the court hearing next month. We’re planning for a positive outcome. In summary, our strategy is delivering growth in very difficult times. We remain committed to delivering strong operational results and our dividend growth policy. We remain focused on our commercial priorities. We are delivering today and investing in the future, creating a stronger view. Our people have gone above and beyond to deliver these results. I am proud of what we have achieved. I will now hand over to Tadeu, who will take you through the financials.
Tadeu Marroco
executiveThank you, Jack, and good morning to all of you. As Jack pointed out, our first half performance is something we take pride in. We achieved growth despite the challenging conditions we faced. Our unrelenting attention to costs has freed up money to back our growth plans and produce solid margin expansion. The advantages of Quantum are coming through, with phase 1 savings pulled forward into the first half. We generate a great deal of cash and stay dedicated to the leveraging, to raising the dividend and to a 65% payout ratio. Strong results in combustibles lifted revenue by 2.4%, even with a 4% COVID headwind during the first half. Gains in value share and solid pricing, driven by our global brands, more than made up for the decline in combustible volume. Price mix for the first half came in strong at 8.5%. That mirrored delivery of more than 80% of the pricing planned for the full year along with rollover benefits from solid pricing in 2019. This means that in the second half we will be up against a strong pricing comparator. Industry elasticity and affordability dynamics are still robust. So far we have found little sign of faster down trading. Beyond that, rolling out our revenue growth management initiatives lets us price in a more targeted way and handle discounting more effectively using data.
Tadeu Marroco
executiveMoving on to how we performed by region. Across each of the four regions, we've increased both value share and volume share. Regional financial results mirror the varying degrees of exposure those regions have to developed versus emerging markets, and revenue growth came in stronger in the U.S. and ENA. Results in APMEA and AMSA show what COVID has done in emerging markets. In the U.S., as Jack already went through, revenue and profit were up nearly 10%, powered by value share gains, solid pricing, and industry volume that beat expectations. In ENA, total cigarette volume share rose 50 basis points, while value share climbed 10 basis points, fueled by robust results in Russia, Turkey, Italy, and Romania. Volume in Russia got a lift from trade stock movements during 2019 and 2020 tied to gearing up for track and trace implementation. The EU menthol ban took effect in mid-May, though full rollout has been pushed back in certain markets because of COVID. It's still very early days, but so far the results look encouraging. In key markets, our consumer retention rates presently exceed 100%. We're increasing our share of consumers within the total nicotine market. That's being driven by cross-category consumer activation, our differentiated combustibles products, and the strength of our new category menthol portfolio.
Tadeu Marroco
executiveWhen it comes to APME, we're still picking up both volume and value share, even with the tough conditions created by COVID, the postponed enforcement of minimum pricing regulations and the tax increase in Indonesia, and more illicit trade in Pakistan. Over in AMSA, gains in volume share plus solid pricing meant revenues fell just 1%. That was a really strong result considering the sales ban in South Africa and the factory shutdowns and lockdowns ordered by governments in countries such as Mexico and Argentina. This slide shows how industry volumes have performed differently in developed versus emerging markets. Take Germany: domestic purchasing rose because border closures limited cross-border volume and reduced outbound tourism, which drove industry volume growth. In emerging markets, things are more mixed. Stricter lockdowns have hit volume in countries such as Mexico and Vietnam. By contrast, border closures have curbed illicit trade and lifted duty paid volumes in markets such as Brazil, while consumption in Russia has held up relatively well. Turning to operating margin: we're freeing up the funds to back the growth agenda, with margin growth delivered and more investment put into new categories, continuing the step-up in new category support carried over from the second half of last year. The 80 basis points increase in the first half comes on top of a strong performance in earlier periods, and that's despite a 50 basis points hit from transactional effects.
Tadeu Marroco
executiveAnother strong performance from the business drove this, more than offsetting the incremental costs tied to COVID. A 400 basis points improvement came from strong pricing, continued cost control, and the acceleration of Quantum. We are realizing the benefits of phase I of Quantum. Beyond greater organizational speed and agility, significant cost savings are being delivered by Quantum. Phase one savings have been accelerated, with GBP 240 million realized in the first half. Phase II will build on the success, with the organization expected to be ready for project rollouts from the beginning of 2021. EPS grew strongly and was up 6.6% in constant currency, driven by our good operational performance. Earnings growth also benefited from a lower underlying tax rate and a strong contribution from associates. Our share of income from associates, mainly ITC, is expected to reflect the impact of COVID in the second half. A full year underlying tax rate slightly lower than the previous guidance of 25.5% is expected, as the impact of several one-off items in the first half are diluted over the full year. Extrapolating current spot rates, a currency translation headwind of around 2.5% on adjusted EPS growth for the full year is expected.
Tadeu Marroco
executiveCash conversion during this period came in strong at 80%, or 73% when you adjust for the benefits from deferred U.S. tax payments and the impact of COVID-related stock builds. That remains materially above prior year periods. During the first half, we took further steps to strengthen our liquidity position through bond issues, the establishment of bilaterals, and renegotiating our RCF. Our maturity profile stays very manageable, with an average maturity approaching nine years and close currency matching. After repaying GBP 2.3 billion in July, we have just GBP 1 billion left in 2020. In the 2021 financial year, we expect to be able to prepay a proportion of our 2022 maturities, as we have done previously. We remain focused on maximizing cash generation and deleveraging the balance sheet. We expect to deliver at least 90% operating cash conversion and are on track to end 2021 with adjusted net debt to adjusted EBITDA around 3x. We continue to expect gross CapEx for the year to be around GBP 650 million, broadly in line with adjusted depreciation. Our priorities remain unchanged. To delever the balance sheets while maintaining our commitment to dividend growth and our 65% payout ratio. These results demonstrate our continued resilience.
Tadeu Marroco
executiveOur expectation for 2020 revenue still includes a COVID-related headwind of roughly 3%. Although the second half carries uncertainties, we remain on course to meet our 2020 guidance: constant currency revenue growth of 1%-3% and EPS growth in the mid-single digits. All things considered, we are doing well given difficult conditions. The changes we are implementing across the business, together with ongoing investment in our brands, will put us in a stronger position when we come out of this crisis. With that, I will hand back to Jack now for his closing remarks.
Jack Bowles
executiveThank you, Tadeu. Delivering these results has required extraordinary effort from our people. Even in these exceptional circumstances, our multi-category strategy is producing growth in revenue, profit, and earnings. Across every region, the strength of our brands in new categories and in combustibles is fueling gains in both volume and value share. The diversity of our geographic footprint supports us as we navigate the environment with agility. Thanks to our three clear commercial priorities, we have made good progress in 2020. A stronger, simpler, and faster organization is what we are building. As these strong results show, the strength and resilience of our multi-category business lets us deliver today and invest for the future. There is strong energy in the business. With a clearly defined purpose to reduce the health impact of our business, we are building a better tomorrow. Against our clearly defined ambitions, we have made good progress in 2020, and post-COVID, we remain committed to our medium-term guidance. While the future is unknowable, I am confident that we will exit this crisis stronger than we entered it. Thank you. A conference call Q&A will be held at 8:30 A.M. U.K. time, where there will be an opportunity to ask questions.
Jack Bowles
executiveI appreciate you all tuning in, and please take care of yourselves.
Operator
operatorGood day, and thank you for joining the BAT 2020 Interim Results Q&A conference call. Throughout the Q&A session, everyone will be in listen-only mode. Should you wish to pose a question, kindly press star one on your telephone keypad, and please make sure your lines stay unmuted. I'll now pass the floor to Jack Bowles, Chief Executive. Thank you.
Jack Bowles
executiveGood morning, everyone, and thanks for joining BAT's 2020 Interim Results Q&A session. I'm Jack Bowles, Chief Executive, and with me on the call is Tadeu Marroco, Finance Director. As you'll have seen in this morning's announcement, our multi-category strategy keeps delivering growth in revenue, profit, and EPS in the first half despite exceptionally challenging circumstances. We've carried on investing in our portfolio. The strength of our brands across new categories and combustibles is driving volume and value share growth in every region and enabling strong pricing. Over the last 12 months, we've attracted 2.7 million additional consumers to our non-combustibles portfolio, which now accounts for 10% of our group revenue. Thanks to our diverse geographical footprint and the increased agility that Quantum has brought about, we've adapted rapidly and are successfully navigating the challenges of COVID. There is strong energy in the business. We're building a better tomorrow with a clearly defined purpose to reduce the health impact of our business. Along with our three clear commercial priorities, this has enabled us to deliver a strong performance in the first half of 2020. I'll now hand the call over for your questions. Operator, please, may I take the first question?
Operator
operatorRey Wium with SBG Securities is first in the queue with a question. Rey, your line is open.
Jack Bowles
executiveMorning, everyone.
Rey Wium
analystHey Jack, hey Carlos. Thanks for letting me ask a couple of questions. I’ve got one question that’s specifically about South Africa.
Jack Bowles
executiveCorrect.
Rey Wium
analystI’d simply like to understand how your market share position is affected once matters are, say, resolved. Because I’m certain that, obviously, it has to be damaging brand equity. And tied to that: the players now active in the market—are they essentially what I could call non-duty-paid cigarettes, or are they more like, perhaps as in Brazil, paying half the duties or underpaying them? It would be quite interesting just to hear your perspective on how this is in fact affecting your business, because clearly this isn’t a decent situation.
Jack Bowles
executiveRight. It's a really complicated situation. Ultimately, governments are the ones making decisions about COVID. What I can say — since, as you're aware, there's litigation ongoing right now — is that I'm not able to go into much detail on that. The way the market actually looks is this. Cigarettes are banned. Alcohol has been banned again, so the government is losing a great deal of revenue. On top of that, the market has gone entirely 100% illicit, and prices in the market have tripled. You've got a situation where consumers can't get legal products, and even when it comes to illegal products, availability is somewhat inconsistent. In that climate, as I mentioned, we have a legal case, and we're getting ready, naturally, to make a mother of all returns once the market reopens. Obviously, our brands are very strong. As you saw in Q1 of the year, with a really strong showing in South Africa. In 2019 as well, we registered revenue growth, along with growth in volume and market share. Our brands, I promise you, are very strong in South Africa and will make the mother of all comebacks the moment it reopens.
Jack Bowles
executiveTadeu, is there anything you’d like to add?
Tadeu Marroco
executiveNo, I believe you've put that nicely.
Rey Wium
analystAlright, sorry. I’d also like to ask, just on the excise tax side, that’s probably a bit more of a medium-term matter. Obviously, when governments come under pressure, the excise tax tends to be the first lever they pull. I’m not sure whether you’ve seen any signs of possible excise issues further out, and whether you can share anything you took away from the period after the global financial crisis regarding what usually occurs with excise taxes.
Jack Bowles
executiveThank you so much. Broadly speaking, as you've witnessed previously, we're exceptionally skilled at steering through situations like this. As I mentioned, current prices stand at 3x what they were after the lockdown. There's plenty of room to maneuver. As I said, South Africa is going to see the mother of all comeback. Our brands are very strong, and there will be a few skirmishes, but we'll handle those. Our position in South Africa is very strong. Not a single person across the entire company was let go, the full sales force is operational, and we'll make certain we reclaim our position in South Africa. Once it reopens, I believe the situation will be extremely vibrant.
Rey Wium
analystAlright, thank you.
Jack Bowles
executiveI appreciate that.
Tadeu Marroco
executiveYes. May I add something on the tax angle? For cigarettes, total taxes as a share of government revenues generally aren't as large as people initially assume. Ultimately, it falls between 1% and 2%, and in an extreme case it can reach above 5%. If you set the tobacco excise contribution against government debt as a percentage of the GDP, it's really not very material. I don't believe these assumptions that we're necessarily going to see many excise hikes hold up, though this brings side effects like illicit trade, which we all know about. In South Africa's case specifically, they have just passed the new budget, in which they also kept the excise rates for another year. I just want to put this into perspective.
Rey Wium
analystI appreciate that.
Operator
operatorAppreciate that, Rey, for the question. Our following question comes from Gaurav Jain at Barclays, who is on the line. Your line is now unmuted, so please go ahead.
Gaurav Jain
analystYeah.
Jack Bowles
executiveGood morning, everyone.
Gaurav Jain
analystGood morning, Jack, and good morning, Tadeu. I appreciate the chance to speak. My first group of questions concerns Japan. In THP, your volumes have fallen 6%, whereas at your main competitor in that market, volumes rose 9% in 1H 2020. What I'd like to understand is whether you're picking up volume share. It would be very helpful if you could explain the reason revenues have declined.
Jack Bowles
executiveApologies, I missed the latter half of what you asked. My apologies.
Gaurav Jain
analystWhat's causing the revenue decline in Japan on the THP side? I'd find that really useful.
Jack Bowles
executiveRight. Yeah, Japan is a larger market for THP globally, as you know. We’ve got glo there, and it has performed extremely well. Naturally, glo sens didn’t achieve what we’d hoped, though glo Pro turned out to be a big success. Building on that, we introduced glo Hyper, and our latest exit share stands at 5.9% for glo in Japan and 1.3% for Hyper. That’s a very, very strong result. Yes, there are stock movements, but consumer acquisition is going extremely well, and our device share is very high. We’re in a good position. Tadeu, would you like to add anything?
Tadeu Marroco
executiveSure. Let me take you back to October 2019, when there was a further step in the THP excise harmonization in Japan, and at that point we were already carrying a JPY 10 pass-on tied to the rise in Japan's consumption tax, which works the same way as VAT. That rate went from 8 to 10. Because of competitive considerations, we ended up absorbing that excise harmonization. As you know, we constantly watch relative pricing in the market and so forth. That is the main reason we see this revenue reduction in Japan. On the volumes you are asking about, in November and December of 2019, those volumes came from the usual year-end loading, together with stronger shipments to support the Pro national expansion. If you look back to that period, we were launching our induction technology, which we call Pro, along with the device and glo nano. At the same time, we had significantly improved consumables that were also being launched. Essentially, new device penetration efforts were paired with higher IMNs of consumables at that moment. That explains why we see a sales dip in January this year. To give you a sense of it, comparing February to June 2020 against February to June 2019, our volumes would be up 5.2%, which shows how depressed our sales were in January 2020 because of the dynamics I just described.
Gaurav Jain
analystAll right, that's really useful. My next question concerns the e-cigarette PMTA process, and it's only one month off now. I believe you said at some point that it could unlock retail sales worth nearly GBP 2 billion for you, if my memory serves. Given what you've observed in the market over the past few months, what are you expecting at this point?
Jack Bowles
executiveSure, the U.S. PMTA process takes a long time. As you're aware, that deadline has already been pushed back before. Our figure was $1.5 billion in contestable space becoming available by the end of 2021. What remains to be seen is how quickly the FDA will reach its decisions once all the submissions are in. We're in a very strong position with all of our submissions, and it will take some time, but even so, what you're seeing in the U.S. is that closed systems are gaining traction, and at the same time, the expense of taking products through a complete PMTA is quite high. That's the reason we said a potential contestable space of $1.5 billion lies ahead. As you know, with our SKUs in the U.S. and Alto, as you saw from the performance, we're doing extremely well. Alto has tripled its share in the U.S. year on year, so we're performing extremely well and we'll keep bringing consumers to these platforms. Tadeu, would you like to add anything?
Tadeu Marroco
executiveYeah. Look, they've just shifted the goalposts to September now. As Jack said, we're very well prepared to make all the submissions. We've already submitted 29 SKUs in Vapour. Now it's just a question of waiting for enforcement to materialize in the market. We've tripled our share with Alto in the U.S., so we're doing extremely well. The PMTA takes a bit more time, and that will create a lot of contestable space, and we're growing in that environment.
Gaurav Jain
analystExcellent, that’s really useful. One final question from me about the U.S. political landscape and those bills banning flavors — in particular SB 793 in California. Obviously, menthol accounts for half of your cigarette portfolio. If a flavor ban were to take effect in California, how do you anticipate that would affect your business?
Jack Bowles
executiveThat's a really good question, and thanks for bringing it up. Let me just give everyone a quick reminder about geography. The U.S. covers a great many states — 50 of them — and each one differs when it comes to price, excise, and regulations. What happens in one particular location in the U.S. has to be kept separate, I think, from the total U.S. market. There's already a lot going on, many different situations when it comes to pricing and when it comes to consumer access across the various states. I have to say these are skirmishes that aren't all that important, and we'll handle them as we go along. The key point is that our brands are very strong, that we can already navigate circumstances in the different states, and that we'll keep doing so. Some skirmishes will come up, but the overall U.S. market is very favorable. We're seeing a lot of progression in our market share and our value share across the different portfolios. Our position is a very strong one. Tadeu, would you like to add?
Tadeu Marroco
executiveSo yes, I believe you're aware that Reynolds has filed a legal challenge regarding bans on local flavors. We can't discuss the details of active litigation, but our view is that certain flavored products matter, since they assist adult smokers in moving away from cigarettes. The flavors we sell give adult smokers a choice they find acceptable as they seek potentially less harmful alternatives to cigarettes. That's something federal law ought to enforce, in my view. And as Jack mentioned, the dynamics differ considerably from state to state.
Gaurav Jain
analystExcellent. Many thanks.
Jack Bowles
executiveThanks a lot.
Operator
operatorThanks, Gaurav. Our next question comes from Owen Bennett at Jefferies. Owen, your line is unmuted now, so please go ahead.
Jack Bowles
executiveHey Owen, how's it going?
Owen Bennett
analystYes, that's fine. Thanks a lot.
Jack Bowles
executiveYour notes are something we always go through with a great deal of interest.
Owen Bennett
analystAppreciate it. At least somebody is. I have one quick question, circling back to PMTAs and Modern Oral. I was wondering what your plans might be regarding a PMTA for possibly higher nicotine strengths as well as additional flavors. Considering that gap in your portfolio, is that something you're aiming to address sooner rather than later? Thank you.
Jack Bowles
executiveYes. On the PMTAs for oral tobaccos, everyone’s submissions will go in at the proper time. As you correctly note, and as we’ve mentioned in various communications, we’re in good shape in 4 mg and below, while flavor is where we have a gap. Keep in mind that Modern Oral accounts for 1% of overall nicotine consumption in the U.S., versus 10% for traditional oral. It’s a small segment right now, and we’re performing well in 4 mg and below. Every PMTA is prepared and ready, and our aim is to broaden the portfolio into higher nicotine levels. We’ll update you once the solutions are in place. That will require some time, but it doesn’t worry me much. We’re putting strong effort into this topic, and there are plenty of other priorities we need to handle in the U.S. This is a midterm matter, and I give you my word that we’ll address it.
Owen Bennett
analystAll right. Thanks a lot. I appreciate that.
Jack Bowles
executiveRight.
Operator
operatorThanks, Owen. We’ll take the next question from Nik Oliver at UBS. Your line is unmuted now — please go ahead.
Nik Oliver
analystHey there, good morning, everyone.
Jack Bowles
executiveHi there, good morning. How's it going?
Nik Oliver
analystYeah, good, thank you. Just a couple from me. First, about the investment in new categories. Last year, if I'm right, I think you invested GBP 500 million in H2. How should we see the GBP 250 million investment in H1 in that context? Should we expect a further step-up in the second half?
Jack Bowles
executiveRight. First off, as the figures showed, we've handled the opening six months of the year really well, and we're emerging from that first half in a stronger position. Second, we stated a year ago that thanks to Quantum we have at minimum GBP 300 million on hand to put into the business, and that's exactly what we're doing — as you saw, GBP 250 million during the first half, in an environment that was very challenging. I'm firmly of the view that we must take the right steps for the business across the mid to long term, and make sure we're putting money where the platforms are performing extremely well. We've witnessed the traction across the three platforms — Modern Oral, THP, and e-cigarettes. We will keep investing. The comparators are going to differ between H1 and H2, but my view is that we need to seize the opportunities as they come along and invest where it matters for the business over the mid to long term. Tadeu, would you like to add anything?
Tadeu Marroco
executiveLet me just remind everyone that of that GBP 500 million from last year, a significant portion was spent during the second half of 2019. So in 2020, we're now up against a very strong investment semester. We keep investing through the first half of 2020, carrying on that momentum we began building late last year, when we started putting money into THP as we moved to ENA in markets such as Russia. More recently, we're rolling out glo Hyper in Japan and also in ENA. On Vapour, we've stepped up our investments in the U.S. and there to support our menthol ban strategy. For Modern Oral, we're shifting launches toward emerging markets, Pakistan being one example. We're also putting money into capabilities around social media, listening, e-commerce insights, and design, data analytics, and so forth. Keep in mind that we'll be lapping a half year that was full of investments. We aren't giving any guidance for the full year. That's the one thing to bear in mind.
Jack Bowles
executiveOne more thing I want to mention on that, and thanks, Tadeu, for the point — we've added 2.7 million more non-combustibles product consumers compared with September last year, and that works out to 30% growth in our consumers. That is absolutely massive. What it tells us is that we have a formula that works, first of all when it comes to consumers. Second, it means that with the MAPS system we have in place, we get extremely good consumer insights and know where to launch what. It's about the rollout. As Tadeu said, we made a lot of improvements on the digital side during the COVID period, and we're seeing the results. I mean, Vuse now holds 26% share across the T5 markets, which represent 80% of the global Vapour industry. IQOS has triple share in the U.S., and glo is at its best market share of 5.9% at the end of June. glo in Moscow now stands at 2.8% of total nicotine in June. We're getting some traction, and we want to make sure we invest. We do resource allocation every month. Tadeu and myself are extremely busy on a weekly basis doing the heaviest resource allocation to make sure we keep growing our new category business.
Jack Bowles
executiveLike I mentioned, we've brought in 2.7 million consumers of non-combustibles products. That's huge. But at the same time, we haven't eased off on combustibles at all. Our value share is rising, and our market share has been climbing at record levels over the past few years. Getting the cash and securing the resources to keep investing matters enormously to us. Our investment in combustibles is at the right level. We're seeing the traction, and the pricing environment is favorable.
Nik Oliver
analystAlright, excellent. Just one last question as well.
Jack Bowles
executiveSure.
Nik Oliver
analystTurning to new categories. I believe previously you mentioned that Vapour in Canada, Modern Oral in Scandinavia, and THP in Japan are each generating positive operating profits. Has anything changed on that front, or are there additional markets you could point to that are profitable?
Jack Bowles
executiveI believe we're in a consumer acquisition phase, since a few years back we were somewhat on the back foot, and we've sped up dramatically with far better traction when it comes to developing new products. Previously, it took us 24 months to get from a working prototype to launch. Today that span is 12 months from working prototype to launch, and this will keep getting better. I think given the quality of insights we hold across all four categories — which nobody else has, because we're the only company operating worldwide across all these categories simultaneously. It's more complex, yet we possess a great deal of insight that lets us push forward. Tadeu, would you like to add something?
Tadeu Marroco
executiveYeah, the one point I’d like to make, Nik, when we sum things up, is that the payback in Modern Oral has been quite quick, as I’ve mentioned previously. In every market where we launched, we’ve done extremely well with Modern Oral. You saw revenue rise 70% during the first half of the year. Essentially, all of these are in positive territory within a very short span of time. With vape and THP, it takes longer. Looking at our figures, you just saw a consolidation across all categories in all geographies. I’ve said before that I anticipated, going forward into the years ahead, a smaller operating margin drag from the base we had in 2019. Starting in 2021, given the encouraging performance we’re seeing across every category and the plans we have to further improve gross margin, we expect the impact on the P&L to ease and become more accretive year after year.
Nik Oliver
analystAll right, that's crystal clear, folks. Many thanks for the responses.
Jack Bowles
executiveThanks a lot.
Operator
operatorThanks, Nik. Our next question comes from Adam Spielman at Citi. Adam, your line is now unmuted, so please go ahead.
Jack Bowles
executiveHi, Adam. How are you doing?
Adam Spielman
analystI'm doing well, thanks a lot. Appreciate you taking the question. First off, I'd like to ask about up trading versus down trading in the U.S., and I suppose more broadly around the world. A lot has been said about the fact that down trading is actually what we're seeing in the U.S. But at the same time, your premium brands are performing quite strongly, which I take to be up trading, actually. So I was just wondering whether, in your view, this is a market where up trading is happening or down trading is happening. And then I have a somewhat more general question for afterwards, about the global picture.
Jack Bowles
executiveOkay, sorry, Adam. You know I'm French, so let's begin with the first question. My brain is small. Let's concentrate on that one first. There are a limited number of brands in the U.S. that you need to examine in order to understand. First, you always have to go back to the point that price elasticity in the U.S. is very good, 0.3, 0.4. The second thing is that absolute prices in the U.S. are quite low relative to disposable income and in absolute terms. When a pack of cigarettes costs EUR 10 in Europe, a pack of cigarettes costs 5 to 6 in the U.S., $5-$6. I think there is strong room for pricing, as you've seen over the last two years. On the back of that, some say there is downtrading. I don't see that downtrading in the U.S. When you compare the big three and the non-big three, you see that the non-big three's growth trend has not changed. They're taking pricing alongside the big three, so the price gaps are not significantly widening. The second thing is, there has been some depositioning of SKUs for some competitors that moved 10% of their volume on one brand to a lower price point.
Jack Bowles
executiveSo ultimately, when you look at our Above WAP or premium share rising, as the presentation showed, and our brands staying very strong, that once again proves what marketing really means. You build strong brands and ensure their equity can back up their price position. I believe we're performing extremely well in that environment, and in the U.S., I don't see any significant indications of faster downtrading. As for the rest of the world, in mature markets you observe very few downtrading signals. It's more the case in Germany, for example, because, as I mentioned earlier, the legal market there has grown in size due to the closing of borders to Eastern Europe. It was negative in 2019. Now in 2020 in Germany it's positive. Naturally, consumers are seeking alternatives. Those who used to buy these EVC products are now purchasing more make your own and roll your own and low price points. That isn't downtrading, it's simply a shift in distribution. Premium in developed markets is performing extremely well, and above WAP, meaning above the average price in the market, is performing extremely well.
Jack Bowles
executiveThere's no indication of consumers trading down at a faster pace. Not at all. If you look at emerging markets, the issue there is really product availability along with the lockdowns. In those situations, whenever markets are open, we aren't seeing any acceleration tied to that. The figures you might spot here and there stem more from lockdowns affecting various parts of distribution. Certain countries have their CVSs shut. In others, general distribution remains open. To me, all of this is logical, and it will return to normal. I'll repeat it: no downtrading. Keep in mind, as always, that in any other FMCG category, the price gaps from top to bottom typically run two-fold, 200% and beyond. With cigarettes, you're looking at roughly 25% from top to bottom. Consumers don't purchase toothpaste each month, yet they purchase cigarettes daily. That makes for a far more resilient environment and business, and the price elasticities are solid. Did that answer your question, Adam?
Adam Spielman
analystYes. Thanks. You went slightly past that.
Jack Bowles
executiveI always try, when I'm speaking with you, to go further than what was asked.
Adam Spielman
analystLooking at slide 29 in the presentation pack, something caught my attention: it states that in EMs your volume share rose 70%, yet your value share stayed flat. That's not something I really get.
Jack Bowles
executiveYeah. Tadeu, would you like to handle that one? It has more to do with product availability and markets being locked down. Tadeu, perhaps you could field that question.
Tadeu Marroco
executiveRight. You mean how our share position differs between developed and emerging markets. Adam. Adam?
Adam Spielman
analystYeah, I’m able to hear you.
Tadeu Marroco
executiveYeah. Hi, Adam. You're talking about the various positions regarding how we stand in developed versus emerging markets, right?
Adam Spielman
analystRight. In emerging markets specifically, you've gained on volume share while value share hasn't moved up.
Tadeu Marroco
executiveThat's the dynamic Jack was talking about. In many of those developed markets, where people are paid, say, on a daily basis, and where lockdowns occur, the switching level that usually sits around 10% in those markets rose to 20%. They switch brands for economic reasons, but also because they can't find their brands, and in the end they'll buy a brand that sits at the lower end of the market. It isn't a steady downtrading trend; it's simply a result of the circumstances they're living in. We've tracked this month by month, and we can see it change considerably when you move out of lockdowns versus when you go into them. I think that's what the chart shows — a reflection of some of those movements he was referring to as well.
Adam Spielman
analystAlright, thanks a lot. May I ask something regarding how glo Hyper is being rolled out? The reviews are clearly favorable. You mention that you'll be moving to full distribution across many markets. My question is, what impact will that have? Do you anticipate a kind of? A discontinuity — a positive one — a step change in volume for glo Hyper. Could you give us any indication of your capacity for it during the second half of this year and looking toward 2021 and beyond?
Jack Bowles
executiveAdam, you know how I operate — one step at a time. We've established the proof of concept in Japan. At this point we're at 1.3 share points after a limited number of weeks, under two months. As you're aware, normally in Japan you get three weeks of excitement at the start. After that it dips, as if there's nothing more behind it. What's very encouraging in Japan is that we keep moving forward. Very clearly, on one of the charts in the presentation, we explain why: overall satisfaction with the product has risen. The format is better. There's 30% more tobacco in there. We're extremely strong on everything related to the flavors. We're having success there. We'll need to watch how it continues, and how it starts. Japan is a very competitive market. It's the most competitive market. It still accounts for more than half of total THP volume. We observe this when we run either market research or pilots or limited launches, as in Russia, for example. In Moscow, we have 2.8% in June, and this is a great majority on Hyper. We'll carry out the rollout, and we'll do it step by step to make sure we have the traction we need.
Jack Bowles
executiveAre there any manufacturing problems? No. I'd like to proceed one step at a time so that we pick up the learnings as we go and improve how efficiently our marketing spend pays off. I want to be sure we're learning along the way. I believe we have a really solid product: induction heating along with a boost button. A better format, which was among the issues we faced. A better format when it comes to the consumable's dimensions. We'll keep pushing forward. Our insight is very strong. It's highly promising, and we'll proceed one step at a time.
Adam Spielman
analystIf you were sitting in an analyst's seat, what kind of volume figures would you plug into your model for 2021?
Jack Bowles
executiveUnfortunately, I'm no analyst — as you all know, I'm just a French farmer with limited brainpower. So we need to be clear about the various pieces of this puzzle. As I mentioned, on the manufacturing side there's no problem at all. On insights, things look very positive. On overall acceptance, our conversion rates and competitiveness are extremely high and very competitive, to put it that way. What we have works really well. The next step is the rollout. We need to build the brands. We need to examine the specifics. Recall the MAPS chart I showed everyone at the recent Investor Day. It matters a great deal to understand and to check the consumer satisfaction index as well. That appeared in Paul Lageweg's presentation at the Investor Day. Some markets can see THP do better than others. Take the U.S. — quite plainly, there is no traction on THP at present. There's plenty of traction when it comes to e-cigarette and oral and Modern Oral. I believe it will vary by geography. We know where we intend to launch, and we simply must keep in mind that in certain markets the THP category faces some breaks at the taxation level that may potentially not be sustainable over the mid to long term.
Jack Bowles
executiveWhen products are sold at prices well under what cigarettes cost in certain European markets, consumer satisfaction truly has to be very strong. We'll steer through all of that and ensure we've got the right grasp of it. Our product is a winner. I'll get it launched quickly, though rushing and moving fast aren't the same thing. Speed is what I'll choose over rushing. We're going to make it happen.
Adam Spielman
analystAlright, thanks a lot.
Jack Bowles
executiveThanks, Adam. Take care of yourself.
Operator
operatorThanks, Adam, for that question. Our following question comes from Michael Lavery at Piper Sandler, who is on the line. Michael, your line is now unmuted, so please go ahead.
Jack Bowles
executiveHi there, Michael. How’s it going?
Michael Lavery
analystMorning. Yeah, thanks. How are you doing?
Jack Bowles
executiveThat's excellent.
Michael Lavery
analystApologies if I've asked about this before, but I wanted to check whether you can update us on the disputes involving Florida, Texas, and Minnesota concerning the Kool, Winston, Salem, and Maverick brands. I suppose there are two or three questions here. I understand that Florida's appeals court has held you liable for roughly GBP 100 million, plus the continuing payments tied to that. First, is there still an appeal process available there? Is the matter final? What are the next steps, if any? Second, what does this suggest for the other states that are having similar discussions?
Jack Bowles
executiveMichael —
Tadeu Marroco
executiveJack?
Jack Bowles
executiveMy apologies. Perhaps I'll begin with this one, if that's alright with you.
Tadeu Marroco
executiveRight. That's the latest matter that surfaced yesterday. As you'd expect, Michael, we're not able to comment on it. The sole litigation currently underway — the only thing we're in a position to say is that no near-term resolution is anticipated on our side. It will most likely carry into 2021. Beyond that, we can't discuss it or offer any remarks.
Michael Lavery
analystCould you at least verify that after that, obviously, there are additional appeal stages available to you, from what it sounds like?
Tadeu Marroco
executiveWell, as I mentioned, I believe this will continue through 2021.
Michael Lavery
analystWill that also be true for Texas and Minnesota?
Tadeu Marroco
executiveYeah, well, all 3 of them, that's right.
Michael Lavery
analystYeah. Okay. All right. Thanks a lot.
Jack Bowles
executiveMuch appreciated. Every one of these legal cases gets our full attention. Ultimately, they're finite in number, and the priority is making sure we handle them with the proper time and the proper approach. It's going to take time, as Tadeu mentioned. Time will be required.
Michael Lavery
analystAlright, I've got it.
Jack Bowles
executiveYes. Thanks a lot.
Operator
operatorThanks, Michael. Our next question comes from Jon Leinster at Societe Generale. Jon, your line is open, so please go ahead.
Jon Leinster
analystOkay, good morning, and thanks.
Jack Bowles
executiveGood morning, everyone.
Jon Leinster
analystMorning. I have a few things, if I may. During the recorded presentation, I believe you said that early signals in Europe regarding the menthol switchover were going pretty well. I was wondering whether you might expand on that, since some of the implementations have clearly faced delays, that one in particular.
Jack Bowles
executiveAre you talking about the Menthol Ban?
Jon Leinster
analystYou've got it right.
Jack Bowles
executiveAlright, yes.
Jon Leinster
analystClearly, implementation has faced some hold-ups. Specifically regarding Poland, I'd like to know whether it has actually been put into effect. Could you expand on those remarks? I believe you were touching on things like switching between categories and that sort of thing.
Jack Bowles
executiveYes.
Jon Leinster
analystRegarding what we've observed there in Europe, could you speak to that, please.
Jack Bowles
executiveRight. So, as we're aware, this isn't the first instance of a menthol ban taking place. There are cases you can point to in Canada and elsewhere. Typically what you see is really strong consumer retention. And why is that? Because it comes down to combustibles. Why? Since consumers start as smokers, after that they smoke a brand, and after that they smoke menthol — that's the sequence. Retention is usually really strong. As you mentioned, the early signs are that it's been pushed back, both on implementation and on controls. What matters most to look at, I think, is that based on the first data points we're getting from this — though we'll have a clearer read toward the end of the year, once things have settled down a bit — the retention rate is extremely high. And in Europe too, quite plainly, e-cigarette ranks number one by number of consumers in Europe, well ahead of every other category. There's solid switching when consumers wish to stay with menthol. They move to e-cigarettes, and we're very strong in e-cigarettes. In Europe, we lead in e-cigarettes. On consumer retention, we're at a positive level.
Jack Bowles
executiveThe initial indicators look really strong. Poland and every other country included. We’ll need to watch and give it a few months to play out. Between combustibles, as I mentioned, smokers are smokers above all—it comes down to the brand, to nicotine, and to flavor. What matters, I believe, is recognizing that there’s no revolution here. Canada showed the same thing. Other markets showed the same thing. This is simply something we can handle very well.
Jon Leinster
analystAll right. Thanks. And second—
Jack Bowles
executiveYes.
Jon Leinster
analystI think, once more, there was a chance of some legislation in Russia. Clearly, the Modern Oral segment was essentially prohibited for a period. Is that right? Is there a likelihood-
Jack Bowles
executiveYeah.
Jon Leinster
analystSo, will Russia go ahead and make it legal?
Jack Bowles
executiveWe are an extremely responsible business, and that is the foundation. Some U.S. players in e-cigarettes had gone overboard with consumer activation, had reached consumers who were too young, and had done excessive digital work. That generated significant issues. If I may, my approach remains unchanged and is very consistent and logical relative to the past: we seek a level playing field for commercial activities, and we seek rules that place consumer protection first. When we observed late last year in Russia that certain small players were placing nicotine levels in their pouches at more than 10x anything imaginable, we ourselves approached the government and stated that a new regulatory framework for Modern Oral was needed in Russia. If that could not be accomplished quickly, a sales ban would be the correct path, and that is what occurred. It now takes some time for a regulatory framework to be established, because I do not want that category built on sand.
Jack Bowles
executiveMy goal is for that category to rest on a structure and base that lets us use our strengths—namely brand quality, products that people want at low prices, and product quality within a sustainable setting. I believe that was the correct strategy for us to adopt there. Once the new regulatory framework is set, we will move at full speed, since we know from the first months when we were present in that market before the ban that we performed very well with Modern Oral, just as in every other country we entered too. In my view, Modern Oral has considerable pull, because if you recall the consumer moments—I have said this before—for cigarettes you had roughly 20 consumer moments. Today you have about 5 for combustibles, which means 15 remain to be won back for consumers through other product forms. I believe the opportunities are substantial. I would rather proceed step by step and secure long-term sustainability for the business than face a crisis with additional players introducing product definitions that do not fit our company's purpose, which is to lessen the health impact of our portfolio going forward.
Jack Bowles
executiveDid that cover what you were asking?
Jon Leinster
analystYeah, so I suppose that means, for Russia, you're not anticipating the ban will go on forever. You do expect that at some point it will be lifted.
Jack Bowles
executiveSure, absolutely. It really comes down to identifying the right moment and how the new Russian regulation takes shape, and after that we go full throttle. We're aware the products perform well in that market. As I mentioned, we've had success during the months when we launched. There's demand for this category in Russia.
Jon Leinster
analystAll right. And finally, if I could, a broader question?
Jack Bowles
executiveSure.
Jon Leinster
analystComparing prices, I think, as you yourself noted, gets quite hard—harder in the second half. I'm aware there's been some industry chatter about prices being delayed, perhaps not surprisingly, given the COVID situation. So should we then expect a fairly large drop-off in the price mix versus what we saw in the very strong first half?
Jack Bowles
executiveEvery one of our competitors differs when it comes to geographies and similar factors. What I can say is that in the U.S., first of all, you have witnessed a really robust pricing environment, and you saw that in 2019 as well. You have seen that the market size in the U.S. is holding up reasonably well during the first half of the year. Price elasticity in many places sits at 0.3, 0.4 in mature markets, and those account for 75% of our revenue worldwide. I believe there is still room for pricing, and I think those comments were perhaps tied more to particular countries and particular geographies. We are not seeing major pricing. We had a great deal of pricing in H2 last year, so the comparator is going to be high. Still, the pricing environment is strong. There are certain issues in Indonesia, where the minimum price is delayed. Indonesia — when you understand Indonesia, what you know is that when an excise increase happens at the beginning of the year, the price gets passed through during the year, and you reach a neutral point by the half year. Beyond that, it is very progressive over the course of the year.
Jack Bowles
executiveFollowing that, there are price floors and that sort of thing. It has a very big effect in Indonesia. The market there has fallen sharply, though that is mostly one location. Everywhere else, the pricing environment looks strong. Tadeu, would you like to add anything?
Tadeu Marroco
executiveRight. The reason we pointed to the second half is simply to give some perspective. Our guidance for this year is out there: revenue growth of 1%-3%. That's factored in here. As Jack mentioned, pricing is still quite strong. There are a few outliers driven by disruption, as you noted, but that's far from most of it. More importantly, 84% of the price we expect for the year is already captured. I believe all of that is already reflected in our assumptions.
Jon Leinster
analystAlright, thanks a lot.
Jack Bowles
executiveMuch appreciated.
Operator
operatorThanks, Jon. We’ll take the next question from Nico von Stackelberg at Liberum, whose line is now open — you’re unmuted, so please go ahead.
Nico von Stackelberg
analystHello there. Good morning, everyone. Trust you're doing fine. I'd just like to pose one brief question.
Jack Bowles
executiveGood morning, everyone.
Nico von Stackelberg
analystCash performance was solid. In the U.S., some excise and corporate tax payments got deferred. Any sense of roughly when that should flip back? And on that note, cash flow conversion came in strong, and you still expect conversion to stay above 90%. What underpins that confidence for the full year?
Jack Bowles
executiveTadeu is someone who carries a great deal of confidence.
Tadeu Marroco
executiveYes. Hi, Nico. Well, yes, we got this lift from the tax deferral. If you look at our conversion on the excise that was deferred in the U.S., about $800 million, we also had to deal with very high inventory levels because of security stocks in inventories resulting from COVID, adding $400 million of pressure on our working capital. Strip that out and conversion would be roughly 70%-71%, which is still ahead of last year, and that just shows all the efforts and the discipline we're applying when it comes to cash flow. We expect 95% of this cash to reverse in Q3. We'll be fully done in the second half of 2020. Given the focus we've had on managing cash for some time now, I'm quite confident that we can deliver the 90 plus conversion.
Nico von Stackelberg
analystOkay, thanks. So a quick question about South Africa, really. It's a bit of — I'm sure it's a known unknown — but what are you factoring into the guidance, and maybe the fact that it's a known unknown kind of explains the range at the end of the day. Is that fair, or? I'm just curious what's factored in there.
Jack Bowles
executiveTadeu, do you want to keep going with that? Oh yeah, that's one of those known unknowns. Right.
Tadeu Marroco
executiveYeah. It's a known unknown. We've got that legal case in there, as I mentioned. We've readied the model — it'll come back in South Africa. Prices sit 3x higher than before COVID, so there's plenty of room to operate, and we'll make sure we capture all the benefits. I don't want to give too many inputs on that one since we have a legal case. Getting the court hearing took us some time. We have it now, and we'll take it from there. Also, booze or alcohol, sorry.
Nico von Stackelberg
analystRight, yeah. That's correct. Returning to what Adam asked.
Jack Bowles
executiveCould you say that again?
Nico von Stackelberg
analystLet me return to what Adam asked. I believe his question was somewhat broader in scope, so could we focus on the U.S. for a moment? I just want to get a clearer picture. As I understand it, cigarette industry volumes rose 80 basis points, while your volumes declined.
Jack Bowles
executiveMy apologies — I was still wrapping up the earlier question and didn't catch what you asked. You got a little ahead of me there. I missed it. Could you ask it again?
Nico von Stackelberg
analystRight, of course. My apologies. I didn’t intend to cut you off. Your question concerns U.S. cigarette industry volumes. Industry volumes rose 80 basis points. Your volumes fell 20 basis points, but you state that you picked up 10 basis points of volume share. Is that simply a matter of coverage?
Jack Bowles
executiveSir. Yes. Inventory shifts happen from time to time, and that's always true in the U.S. You shouldn't read that too literally. What matters most is that the market is doing better than our initial expectation. That's the reason we went from four to two and a half. Some uncertainties remain for the back half of the year. In the first half, as you know, we saw extra stock build by retailers and consumers, and that's largely a one-off, whether or not things reverse in the second half. Our view is it won't, but it's a one-off that won't recur in the second half. We also had dilution from the extra trading days in half one spread across the year. There are still some uncertainties regarding how consumers respond to the recent second price increase. Given the economic backdrop, consumer purchasing power dynamics in terms of unemployment levels versus continued fiscal stimulus, and the COVID situation itself with lockdowns easing, some uncertainties persist. That's why we expect the second half to be worse than the first half was. That direct correlation between our volumes and the monthly volumes, yes, those are always tricky given some inventory movement at the end of the period.
Nico von Stackelberg
analystAlright, just one last quick question. The alcohol sector has been rather shrewd when it comes to creating industry regulators that oversee advertising rules. The U.S. experience with IQOS and, of course, what happened in Russia with Modern Oral. I'm just wondering, why hasn't the tobacco industry chosen to set up regulatory bodies that effectively watch over and help manage responsible advertising? It's been a considerable net benefit for the alcohol industry, and it looks like the tobacco industry could gain from that too.
Jack Bowles
executiveYes. That question ties more to the matter of, I think, marketing codes, and in BAT we have very strong marketing codes. Some other companies do, and some don't. The manner in which we conduct business under the marketing code we hold, which we review regularly, is to always stay on the right side of the fence, and to make sure we can have a sustainable business in the short term, mid-term, and long term. Other industries may handle this differently, but the reality is that you have many small players in the industry. There are many small players. We always forget that in the U.S., you might have perhaps 200 different tobacco companies. We're always talking about the big three and the non-big three, but the reality is that there are more than 200 companies. I don't feel there's a possibility of bringing all these people together. It's extremely fragmented. As a leading company in that business, we have a very strong and very robust marketing code that has allowed us to be responsible in how we do our business going forward.
Nico von Stackelberg
analystAlright. Thanks, everyone. I appreciate that. Actually, I believe I may have said something incorrectly.
Jack Bowles
executiveYes. Thanks a lot.
Nico von Stackelberg
analystI was referring to Juul within the United States. Thanks.
Jack Bowles
executiveI appreciate that.
Operator
operatorThanks, Nico, for that question. Our next question comes from Sanath Sudarsan at Morgan Stanley. Amin, your line is unmuted — please go ahead.
Jack Bowles
executiveHello there, how’s it going?
Sanath Sudarsan
analystI’m doing well, Jack. How are you? How is Celerio doing? I hope everyone is well. If I may, I have 2 questions about the U.S., please.
Jack Bowles
executiveCorrect.
Sanath Sudarsan
analystTo begin with, let me try to unpack a bit the U.S. volume growth figure, which has been really robust. Early in the year, you've got Tobacco 21, plus questions about what effect that could have on volumes overall. Then COVID hit. Consumers probably have more income, or discretionary income, at this point. When you consider overall smoking prevalence rates or per-user rates, or perhaps consumers shifting from vaping back to cigarettes, how do you view all these shifting variables and the effect of Tobacco 21 on top of that? So that we have a frame of reference for thinking about 2021, perhaps.
Jack Bowles
executiveLike I mentioned, regarding the U.S. picture, Modern Oral sits at roughly 1%. Traditional oral is at about 10%. E-cigarettes are now very near that same level, that 10%. Combustibles make up the remainder. What we have observed is a deceleration in new categories. Oh, THP, sorry, I left out THP, though it is so small that after 6 or 9 months, I mean, more time is needed before we can say. These categories require a very long period to become established, which is normal. Regarding the shifts we are seeing, there was a crisis in Q3 and Q4 affecting e-cigarettes, which is the larger one. That has bounced back rather well. It grew 20%, which is good. It is returning to the proper levels. We are strengthening our positions in this category. What I consider important is that there is also, let me say, a larger-company mindset connected to this. Why? Because consumers are moving toward closed systems, which is extremely appealing for products you watch it once, and also for business efficiencies. As we stated, Alto will triple its share in the U.S.
Jack Bowles
executiveLooking at it year over year, I believe the broad direction will hold — e-cigarettes should keep recovering over the coming period. You'll see the same picture as right now, with that deceleration we've seen in the shift away from combustibles toward new categories. It's going to take a while before that trend comes back with real force. As Tadeu mentioned earlier, combustibles over the last six months have gained from lower intake from e-cigarettes. E-cigarettes have begun growing once more. All of this moves us the right way. Over the midterm to long term, I think the migration from combustible to the other categories will carry on. At a sensible pace, I'd say. That should give us stronger foundations, and the PMTAs will also help open up contestable space in new categories, since there's still plenty of ground for us to win in new categories in the U.S., and a great deal of potential is already present. We aren't talking about things that could emerge, or people who could become users of these categories. They're already here. There's ample room, which is why we say that for companies such as ours — for us in particular, given the strength of our portfolio in the U.S.
Jack Bowles
executiveWhen it comes to non-combustibles, there's $1.5 billion of contestable space over the coming three years. That is simply enormous. We had to establish these solid foundations, and that's what we accomplished across the past 18 months. All right. The regulatory environment is becoming more predictable, since Mr. Gottlieb has been quite active on Twitter, yet in reality, during the two years he spent in the role, nothing actually changed. It's crucial to keep in mind that there have been certain flavors and developments. To be fair, things have turned out more benign and better than most had anticipated. Tadeu, would you like to add anything?
Tadeu Marroco
executiveYeah. I think what matters more is how the total nicotine category in the U.S. shakes out going forward. Like you mentioned, there's a set, pre-established decline when it comes to FMC, and that's going to occur for the reasons you just pointed to. You'll see shifts across the remaining categories. You need to view the U.S. market as a whole when it comes to nicotine size. This one, we expect to expand over time.
Sanath Sudarsan
analystIf I could just build on that question a bit. You've done a nice job sharing the slides showing how the U.S. nicotine market breaks down. How much change do you anticipate there — or how do you see that shifting, say, across the 10-year window you've laid out for bringing in 50 million new consumers, or 50 million NGP consumers? What's your expectation for how this U.S. market develops across Modern Oral, Vapour, and combustibles, and what portion of those new consumers do you figure will likely come from the U.S.?
Jack Bowles
executiveNaturally, we are engaged in planning, though that has to be adjusted as things develop. What we do know is that closed systems within e-cigarette — the largest category — are expanding fairly robustly in the marketplace. Still, offering figures 10 years out would be entirely premature. I believe we are performing well given present conditions. We have picked up considerable share as of late, and we will keep doing so gradually.
Sanath Sudarsan
analystI appreciate that.
Operator
operatorThanks, Sanath, for the question. Our next question comes from Alicia Forry at Investec. Alicia, your line is unmuted and unblocked, so go ahead.
Jack Bowles
executiveHi, Alicia. Are you there?
Alicia Forry
analystRegarding the U.S.
Jack Bowles
executiveMy apologies. If a question came through, I didn’t catch it. I apologize.
Alicia Forry
analystOh, okay. Is this coming through clearly now?
Jack Bowles
executiveYes, that’s an improvement.
Alicia Forry
analystAll right. In the U.S., Modern Oral is plainly doing better than heated tobacco, and both are relatively new categories in that market. What do you believe explains that superior performance for Modern Oral, particularly given that heated tobacco comes closer to replicating the act of smoking? What can you share about the reasons consumers are shifting to Modern Oral at a faster pace than they are to heated tobacco? My second question concerns-
Jack Bowles
executiveLet's pause here, and then you can ask your second question afterward. Regarding THP, we examine every one of the various categories, and we examine the facts. Up to now, in the U.S., it has not been a tremendous success. For sure, it's a long-term play. As we've stated on many occasions, when it comes to the satisfaction index, you always need to refer to the situation in which a cigarette in Japan is around 3 mg, while a cigarette in the U.S. is around 15, 16. When you heat tobacco, having the same satisfaction as when you burn tobacco is very difficult. Okay. There's a gap there. Also, you have Modern Oral, and it's also on the back of a tradition that already exists in the U.S. of a traditional oral that represents 10% of the market. There is a bit more traction related to Modern Oral, but we'll have to see in time what really happens, because at the moment, it is a category that is interesting, of course, for the long term. Don't get me wrong. At the moment, it is mostly acquisition of distribution from the different players. It is a rollout, and it is a small category that is 1% of total nicotine usage.
Jack Bowles
executiveYou need to give it a little time. It stands to reason that there’s a real opportunity here, thinking about those consumer occasions I mentioned earlier—if you’re dropping the kids at school in the morning, for example, you won’t smoke, vape, or use THP in the car. Modern Oral fits those kinds of occasions. Let’s go one step at a time. Right now, the sharp pickup comes from wider distribution and greater availability across the market. We’ll need to see how things develop from here. The differences you see between markets, or between states, are simply enormous. Everything needs a bit of time to settle down. The portfolios will each have to go through PMTAs to be validated, and after that we’ll see where things go. Globally as a category, I believe Modern Oral is gaining traction, particularly in emerging markets, since in those markets consumers can very rarely afford a device such as a THP device or an e-cigarette device. Those are very costly for them. It’s a very good alternative—a product that’s more acceptable from the consumer standpoint.
Jack Bowles
executiveWe’ll need to wait and see, but we’re running some pilot tests across various markets—including emerging markets—and the initial results look quite encouraging. We’ll proceed one step at a time. All right? Tadeu, would you like to add anything on that?
Tadeu Marroco
executiveNo, I believe that's correct. I think THP is essentially a satisfaction issue, as Jack was explaining. For Modern Oral, 40% of the source of business comes from moist snuff. It's not a surprise you're seeing that when you already have a traditional oral market established, which is exactly the case we saw in Sweden, in the Nordics — that you're going to have 10% each of the segments coming from other products, but it's a more modern way of using the product. There's another 50% coming from other categories, FMC, Vapour, and others. It's a different dynamic from THP.
Alicia Forry
analystYes. My second question concerns emerging markets. You mentioned before that a lot of them are feeling strain because of COVID, which has affected logistics and the way consumers are able to get around in certain of those markets. What I'd like to ask is, how have trends developed, maybe in some of your bigger emerging markets that were under pressure, now that those various countries have come out of lockdown? Was there a substantial surge of pent-up demand, or has the rebound been more of a gradual one?
Jack Bowles
executiveThat's a pretty wide-ranging question, so let me take a stab at it. Consider Brazil, since you're talking about markets that matter a lot to us. Brazil had an illicit share above 50%, while licit volume was shrinking by 6%, 7% year over year, and at times by even more. Our portfolio in Brazil is very strong. Thanks to the lockdown, the borders are closed. With the borders closed, the illicit trade, most of which comes from Paraguay, has dropped quite substantially. You've got army on one side of the border and army on the other. What we did was activate some additional SKUs on Rothmans to capture those consumers who couldn't buy illicit cigarettes. Once we bring them into the portfolio, we begin bringing them into the family, so to speak. What we've observed is that Brazil's legal market grew by 7% at the start of the year. That is absolutely massive. Our market share has risen. By far we have the best portfolio in Brazil, present across all the different price points, and we're reaping the benefits of all this.
Jack Bowles
executiveSo I think you need to look at a market of that kind that's done well. Mexico is another very significant one, and you may have noticed that our share has increased quite sharply there. What's the reason? Because we managed to get the right products into the right locations for consumers, outperforming competitors on that front. We relocated a large number of products, and as I frequently say, we spent over GBP 90 million during the first half of the year on logistics and on shifting products about, so that we could be sure of delivering products to distribution and delivering products to consumers. In certain cases, if you look at Pakistan or Bangladesh, for example, availability is more of a problem. Tadeu, anything you'd like to add?
Tadeu Marroco
executiveThe bigger factor is availability. In Vietnam, smoking is a very social activity, and cigarette consumption. When lockdowns hit channels such as HORECA, for instance, it fell sharply, or during curfews when you can't go out and buy or find your product. That dynamic differs greatly from other markets, like the ones Jack mentioned, where illicit trade is falling because borders have closed. The picture is mixed for us there. On the whole it's negative, which explains the drag. Once lockdowns begin to lift, we expect conditions to recover in a favorable way.
Jack Bowles
executiveAll right, can you hear me?
Alicia Forry
analystI appreciate that.
Jack Bowles
executiveMy apologies — I assumed the call had dropped. That's the upside of this kind of connection, though it's also the drawback. Sorry, was there a question from you that I missed?
Alicia Forry
analystNo, I believe that covers everything.
Jack Bowles
executiveAlright.
Alicia Forry
analystPerhaps, if there's room for just one final question. You mentioned that distribution is shifting somewhat in new categories. Obviously, in mature markets, some vape shops clearly haven't been open, and also their products in the U.S. — they haven't been able to sell all of them. Every flavor has been banned. Do you believe these channel shifts are likely to last after the crisis? Has the marketplace in mature markets changed?
Jack Bowles
executiveSure, that's a fair question. A trend has been building over recent years where shoppers increasingly head to general trade outlets to purchase their products. Vape shops have felt the effect of general trade capturing more sales at present, and closed systems are likewise seeing higher sales now. The specialized segment of these shops finds itself in a different position than it did just a year back. My view is that the shift toward general trade is a positive, since it lets us demonstrate our strength when it comes to distribution, given that we already hold very solid positions across these various channels. That supports how the market develops.
Operator
operatorThanks. That was the final question we had lined up, so I'll pass things back to Jack Bowles now to wrap up today's call.
Jack Bowles
executiveWell, thank you very much. That's quite a few questions. I really appreciate your interest. To wrap up, these are strong results achieved in difficult conditions. Our people have gone above and beyond to deliver them, and what we have achieved makes me proud. During the first half of 2020, we have made good progress. Our priorities are clear. We stay committed to our dividend policy and to our medium-term guidance post-COVID. While the global pandemic creates uncertainty in the near term, we keep adapting and investing in our business. I am therefore confident that we will come out of this crisis stronger than we went into it. We are building a stronger, simpler, faster BAT. Thank you very much for listening, and stay well. Thank you very much.
Operator
operatorI appreciate everyone being on the call today. At this point you’re welcome to hang up your phones. Kindly remain on the line.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete British American Tobacco p.l.c. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to British American Tobacco p.l.c. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in British American Tobacco p.l.c. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.